Clinical Trial Update: One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing one-month dual antiretroviral prophylaxis to prevent resistance mutations in mothers exposed to a single-dose of nevirapine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• NEVIRAPINE (nevirapine)

Snippet

Sponsor: Institut de Recherche pour le Developpement | Conditions: HIV Infections | Phase 2 | Status: COMPLETED